XOMA Royalty Corporation
XOMA Royalty Corporation operates as a biotech royalty aggregator in the US and Asia Pacific. It has a portfolio of economic rights to milestone and royalty payments from partnered therapeutics. The company also focuses on early-stage clinical assets with commercial sales potential licensed to partners. Additionally, it acquires late-stage clinical or commercial asset revenue streams.
Overview
Strengths
- Current Price to Earnings Ratio (15.33) is lower than the sector mean (91.15).
- EV/EBIT (11.42) is lower than the sector mean.
- Strong EBITDA Margin of 100.00%.
Weaknesses
- With a depreciation Potential of -93.25%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Analysts expect revenues to decline in the coming year.
- The company has high debt. Net Debt to EBITDA Ratio (1.35) is higher than the sector mean.
- The company have lower returns than the sector in which it operates. ROIC (1.49%) is significantly lower than the sector mean (6.02%).
Key Financial Data